Osteoarthritis is a painful, disabling condition which is increasing in prevalence as a result of an ageing population. With no recognised disease limiting therapeutics, arthroplasty of the hip and knee is the most common and effective treatment for lower limb osteoarthritis, however lower limb arthroplasty has a finite life-span and a proportion of patients will require revision arthroplasty. With increasing life expectancy and the proportion of younger (<65 years) patients undergoing arthroplasty, the demand for revision arthroplasty after implant failure is also set to increase.
Introduction
Osteoarthritis (OA) is a condition characterised by articular cartilage degeneration, pain and eventual disability with one third of adults aged over 45 in the United Kingdom (UK) having sought treatment for the condition 1 . Disability secondary to OA continues to rise, increasing by 16% between 1990 and 2010 2 and the National Health Service (NHS) continues to spend over £900 million annually directly treating the disease 3 .
Arthroplasty is an effective treatment for end stage OA which has not responded to conservative measures including analgesia and physiotherapy 4 . Two of the most common interventions undertaken are primary total hip arthroplasty (THA) and primary total knee arthroplasty (TKA). According to the National Joint Registry (NJR) 91,698 primary THA and 102,177 primary TKA were undertaken in England, Wales and Northern Ireland in 2017, with greater than 90% of these being for the treatment of primary OA 5 .
A proportion of patients require revision of their primary surgery with the main indications for revision being (rate of revision/1,000 patient-years): aseptic loosening (1.25 THA, 1.25 TKA), pain (0.84 THA, 0.85 TKA), dislocation (0.87 THA), adverse reaction to particulate debris (0.86 THA), infection (0.72 THA,), instability (0.69 TKA), malalignment (0. 38 TKA) and periprosthetic fracture (0.69 THA, 0.16 TKA) 5 . Revision risk increases for each year post-primary arthroplasty and despite modern surgical advances and improvement in implant materials, the overall revision risk has remained relatively static for the last 5 years 5 . Comparing 2010 and 2017 NJR data; the 5-year risk of revision was 2.5% and 2.34% for hips, and 2.7% and 2.65% for knees 5, 6 . When compared to primary arthroplasty, revision surgery is recognised to be more technically complex, and is associated with increased risk of dislocation, venous thromboembolism, infection and mortality 7 .
Furthermore, functional improvement after revision surgery may be less than that from the primary procedure 8 . In addition to being more burdensome at the patient level with a higher risk of failure 9 , revision surgery impacts on a societal level with greater financial implications arising from increased length of hospital stay, operative time and complexity 7, 10, 11 .
With an ageing population, increasing life expectancy and rising obesity rates in the UK, the number of people requiring primary arthroplasty of the hip and knee is set to increase substantially. It is estimated that by 2035, based on the current arthroplasty rates, that the numbers of THA and TKA annually will increase to at least 95,877 and 118,666 respectively, though some estimates are greater 12 . Combining this evidence with a simultaneous increase in the proportion of patients under the age of 65 years requiring arthroplasty 13 it is inevitable that there will be a consequent increase in the demand for revision arthroplasty 14 .
Efforts to reduce the risk of revision have focused on intra-operative factors including reducing contamination at surgery, optimum placement of the prostheses and development of new implants. There is developing evidence, however, from animal studies that 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, commonly known as statins, may influence implant survival following arthroplasty. This article will review the literature examining the potential impact of statin therapy on implant survival including data from epidemiological, animal and human studies.
What are Statins?
Statins are cholesterol modulating drugs that act upon the mevalonate pathway by inhibition of HMG-CoA reductase 15 . Reduction of cholesterol by statins has been shown consistently to improve survival in clinical trials by reducing fatal coronary event 16, 17 . The mounting body of evidence from trials and systematic reviews has led to the widespread use of statins in primary and secondary prevention of cardiovascular events in adults. The annual number of prescriptions of lipid-lowering drugs in England has increased dramatically from 295,000 in 1981 to over 50 million in 2011 18 . Derivatives of mevalonate are required in the post-translational modification of the triphosphate-binding proteins (GTPases) responsible for the regulation of osteoblastogenesis and osteoclastogenesis 19 .
Statin induced mevalonate inhibition has a potentially direct anabolic influence on bone homeostasis by inducing osteoblast differentiation via increased bone morphogenic protetin-2 (BMP-2) expression and osteoblast differentiation whilst inducing osteoclast apoptosis via suppression of nuclear factor kappa B (NFB) 19 .
Statins and Osseointegration of Prosthetic Implants and Bone
Early secure implant stability is important for long-term joint survival. Osseointegration is necessary for implant stability and is a result of direct bone-to-implant contact 20 . It is defined as the direct structural and functional connection between bone and implant such that there is no relative movement between the two surfaces as the implant has been incorporated into the living bone 21 . Poor osseointegration of implants may be a risk factor for arthroplasty failure in the short and long term because of micro-motion at the boneimplant interface which can initiate periprosthetic bone resorption and subsequent loosening 22 . This is particularly true in uncemented arthroplasty, which relies on implants Mundy also demonstrated that explanted neonatal murine calvarial bones demonstrated increased bone growth when exposed to simvastatin, fluvastatin, lovastatin and mevastatin when these compounds where cultured with the bone in tissue culture medium at 1M for 72 hours. Furthermore, their in vivo work demonstrated that lovastatin and simvastatin increased bone formation by nearly 50% in the calvaria of mice when injected subcutaneously over the calvarial bone, three times a day for five days, comparable to that seen with positive control BMP-2 injection and observed an increase in trabecular bone volume following intraperitoneal simvastatin administration 14 days and 4 days prior to sacrifice 23 . Additionally, statins have been shown to induce vascular endothelial growth factor (VEGF) expression. VEGF is a glycoprotein responsible for osteoblast differentiation and an angiogenic factor necessary for vascular invasion prior to bone formation, intercellular communication between endothelial cells and subsequent osteoblast activity necessary for bone growth 24 .
In multiple animal studies, systemic administration of simvastatin after implant insertion has been demonstrated to promote osseointegration, increase bone density around implants and crucially, to increase the mechanical strength/stability of the bone-implant interface [25] [26] [27] [28] In addition to systemic statin administration it has been proposed that local application of statins (particularly fluvastatin) to implants may promote similar osteogenic effects, increasing mechanical strength and improving peri-implant bony calcification [30] [31] [32] .
Masuzaki et al gave a single injection of fluvastatin impregnated microspheres to rats with tibial titanium implants, this demonstrated enhanced bone growth and bone contact at 14 days as demonstrated by staining and microscopy around the implant and was accompanied by an increased bending strength, as measured by extraction of the femur following implantation at 2 or 4 weeks after surgery followed by three point bending with a universal testing machine 33 . Similar studies have reported encouraging results with simvastatin coated implants, scaffolds and biomaterials 34, 35 . Topical application of statins may therefore confer the potential beneficial osteogenic effects outlined previously but Osseointegration generally occurs within 3 months of primary arthroplasty 36, 37 . Therefore pre-loading with statins prior to primary arthroplasty and early statin use in the initial weeks and month's post-implant insertion theoretically could be associated with a reduction in complications as a result of sub-optimal osseointegration such as implant stem migration, periprosthetic fracture and loosening as a result of failure of trabecular bone ingrowth 38 . This is supported by animal study data from Li et al who demonstrated early use of statins after implant insertion promotes peri-implant bone growth, and discontinuation of statins in this early period leads to rebound bone resorption 29 There have also been reports of adverse effects to osseointegration with topical statin administration 29 , Pauly et al investigated the effect of locally applied simvastatin to intramedullary nails in rat femurs and found impaired implant integration compared to controls in the form of reduced implant-bone contact and reduced new bone formation 35 .
Statins and Periprosthetic Osteolysis (PPOL)
PPOL is the gradual, progressive resorption of bone and subsequent reduction in bone density around the bone-implant interface in THA and TKA 39 . It has been established that the initial trigger for this process is activation of phagocytic cells in response to wearrelated debris particles released from the bone-implant interface following arthroplasty 38, 39 .
Specific articulation surface debris such as ultra-high molecular weight polyethylene (UHMWPE) have been implicated in phagocyte activation and the subsequent osteolytic cascade weakens the bone-implant interface. This process is generally asymptomatic and can go clinically undetected until there is decompensation and biomechanical instability.
Symptomatic PPOL with aseptic loosening presents late and commonly revision
arthroplasty is required to salvage joint function. Monocyte/macrophages and their derivatives (e.g. foreign body giant cells and osteoclasts) have been implicated in the resorption of bone and PPOL in arthroplasty since early 1990 42 .
There is an established research base for a class of drug known as bisphosphonates (BP) in inhibiting osteoclast formation and function, this is facilitated by their interaction with the mevalonate pathway by inhibition farnesyl pyrophosphate (FPP), downstream of the influence of statins. Some authors have highlighted the potential benefit of BP in arthroplasty survival in human 43, 44 and animal 45, 46 models. In a study using data from the Danish Hip Arthroplasty Register (DHAR), BP use for more than 240 days was associated with a reduction in the relative risk of revision of 0.58 (95% CI; 0.32-1.05) for all indications 44 . More recent research identified an associated risk reduction of up to 59% in those starting BP after arthroplasty surgery 43 .
As outlined earlier statins also inhibit the mevalonate pathway up-stream of FPP and therefore have the potential to exert a similar molecular response as BP, inhibiting the osteolytic cascade and reducing PPOL. This hypothesis has been explored in experimental models. A murine calvarial study noted that introduction of UHMWPE particles induced a pronounced bone resorption response when compared to controls. In the group treated with one of the most commonly prescribed statins, simvastatin, this effect was significantly abrogated. Osteoclast numbers were 48.7 ± 7.1 in the UHMWPE group and 6.2 ± 3.1 in the UHWMPE-simvastatin treated group (p = 0:00002) 47 .
Polymethylmethacrylate (PMMA) particles, released in cemented arthroplasty, have also been implicated as a potential trigger for PPOL via production of pro-inflammatory cytokine Tumour Necrosis Factor-alpha (TNF-α) by human monocytes. An in vitro experimental model of PMMA induced inflammation using human peripheral blood monocytes has suggested that the potent HMG-CoA reductase inhibitor Cerivastatin significantly inhibited this response via the intracellular Raf-MEK-ERK pathway 48 . In a case control study of patients with radiologically detectable femoral osteolysis in THA, the authors compared statin "ever-users" and "never-users" at five years post-THA. Crude risk ratio of femoral osteolysis in the ever-use cohort was 0.36 (95% CI 0.14; 0.92) when compared to neverusers. The relative risk ratio after adjustment for confounders (age, sex, activity level, BMI, diagnosis, bearing surface, type of stem) was 0.38 (95% CI 0.15; 0.99). This analysis did not have sufficient follow-up length to determine whether the risk of revision was lower in the statin ever-use group 49 .
Pro-inflammatory cytokines are considered to be major mediators of osteolysis and ultimately aseptic loosening; three of the most widely implicated are Interleukin-1 (IL-1), Interleukin-6 (IL-6), and TNFα 50 . Experimentally it has been demonstrated that TNFα upregulates IL-1 and IL-6 and plays a pivotal role, both directly and indirectly in the activation and recruitment of osteoclasts with subsequent induction of PPOL in THR 51 . TNFα production is up-regulated in experimental and clinical models of osteolysis, this upregulation is further associated with particulate wear debris in vitro and in vivo 50, 52, 53 .
Similar molecular up-regulation of both IL-1 50,54,55 and IL-6 50, 56 has been reported in aseptic loosening models.
The presence of cells releasing IL-1, IL-6 and TNF has been directly correlated with the severity of osteolysis in THA and the authors suggest pharmacological modulation of these pathways may be a potential target for inhibition of prosthesis loosening 57 . As outlined previously there is evidence to suggest that Cerivastatin inhibits PMMA induced inflammation in vitro via abrogation of the production of TNFα 48 .Cerivastatin also reduces production of the chemokine monocyte chemotactic protein-1 (MCP-1), which facilitates migration and infiltration of leukocytes into tissues 48, 58 . Simvastatin has been demonstrated experimentally to inhibit particle-mediated induction of IL-6 gene expression in human osteoblasts treated with titanium 59 . Aseptic loosening and PPOL resulting from inflammatory processes occurring over a longer period of time may theoretically be reduced by long term statin exposure, with statin administration potentially reducing late onset complications. These data are summarised in Table 1 and a mechanistic model of statin effects is presented in Figure 1 .
Pharmacoepidemiologic Evidence of a Role for Statins in Arthroplasty Survival
There is growing observational evidence which suggests that statins may impact on arthroplasty survival. Using data from the DHAR, 2,349 patients who had THA between 1996 and 2005 and also had revision arthroplasty during this period were identified 60 . In a multivariable, propensity-score matched conditional logistic regression model, the relative risk (95% CI) of revision in those exposed to statins, compared to those unexposed was 0.34 (0.28 -0.41). Statin exposure was not modelled in a time dependent manner but was more crudely assigned as 'ever vs never' statin exposure. 61 . In total, data from 189,286 participants were analysed. In the primary analysis, statin exposure was modelled in a time-dependent manner from the date of the primary THA/TKA. In a time-dependent multivariable Cox regression model including data from both cohorts, statin exposure was associated with a small though significant reduction in risk of revision (incident rate ratio=0.9; 95% CI, 0.89, 0.96). Lalmohamed et al demonstrated that depending on the epidemiological study design used there can be significant differences calculated in incidence ratio of revision surgery. A more recent analysis using CPRD data sought to further investigate association between statins exposure and risk of revision following THA/TKA and also the impact of duration and timing of statin exposure on revision risk, using propensity score adjusted Cox models 62 .
Postoperative statin exposure was modelled as a time-varying variable and a total of 164,224 participants, who had a THA or TKA between 1988 and 2016 were included. Of those exposed to statins following THA/TKA, 852 (1.3%) had revision arthroplasty, compared to 2,648 (3.1%) of those unexposed; adjusted hazard ratio for revision in those exposed vs those unexposed, 0.82 (0.75, 0.90). Similar results were seen in participants who had a THA 0.86 (0.76, 0.98) and TKA 0.76 (0.66, 0.88). Considering the timing of the first postoperative statin exposure, exposure in the first 5 years following surgery appeared protective; compared to those who were not exposed to statins, the hazard ratio (95%CI) of revision in those first exposed to statins in the periods 0-1 and 1-5 years after the primary surgery was 0.82 (0.74, 0.91) and 0.76 (0.65, 0.90) respectively. There was a small protective effect of exposure to statins > 5 years following primary surgery, though the confidence intervals included unity. Compared to participants exposed to statins for a total duration of less than one year, exposure for 1-2, 2-3, 3-4, and 4-5 years did not appear to be associated with THA/TKA revision risk, though exposure for a total duration of >5 years was associated with a reduced hazard ratio for revision, 0.74 (0.62, 0.88) 62 .
Conclusion
In this article we present a broad review of the evidence of the effect of statin therapy on bone biology and risk of revision arthroplasty. There is some evidence from animal and in vitro models to suggest that statin therapy may promote osseointegration and reduce periprosthetic osteolysis. Data from observational clinical studies support a weak effect of statins on bone however there are significant limitations to the interpretation of these data, such as the potential for unmeasured confounding factors to influence results and improvements in surgical technique and implants during the study period. Currently there is inadequate evidence to support use of prophylactic statins in revision surgery.
Taken together the published literature suggests that; although there is likely an association between statin therapy and reduced revision risk in lower limb arthroplasty and a body of mechanistic evidence from animal models, the causal relationship is far from clear and there is currently inadequate evidence to recommend clinical prescribing of statin therapy in patients undergoing arthroplasty of the hip or knee. Given the modest but statistically significant effect of statins on reducing the risk of revision arthroplasty and the large body of in vitro and in vivo evidence which may support these observations, further research is needed to study this effect prior to advocating statin use. 
